Revolution Medicines (RVMD) Stock News

Revolution Medicines announced preliminary safety and antitumor data for RMC-9805, its RAS(ON) G12D-selective inhibitor, in patients with previously treated pancreatic ductal adenocarcinoma (PDAC). The Phase 1/1b study included 179 patients treated with varying doses. At 1200 mg daily dose, the drug showed a 30% objective response rate and 80% disease control rate. The treatment demonstrated an encouraging safety profile with primarily Grade 1 adverse events, including GI-related toxicities and rash. No Grade 4 or 5 treatment-related adverse events were observed, and no patients discontinued treatment due to adverse events.

Revolution Medicines announced encouraging data for RMC-6236, its RAS(ON) multi-selective inhibitor, in treating pancreatic ductal adenocarcinoma (PDAC). The Phase 1/1b study included 127 patients treated with doses ranging from 160mg to 300mg daily. Key results showed median progression-free survival of 8.5 months and overall survival of 14.5 months in second-line KRAS G12X mutation patients. The treatment demonstrated a 29% objective response rate in second-line patients and showed manageable safety profile with primarily Grade 1 or 2 adverse events. The most common side effects were rash and GI-related toxicities, with no treatment discontinuations due to adverse events.

Revolution Medicines has announced the dosing of the first patient in RASolute 302, a Phase 3 registrational study of RMC-6236, a RAS(ON) multi-selective inhibitor, for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). The global, randomized, open-label study will evaluate RMC-6236 monotherapy against standard chemotherapy in approximately 460 patients worldwide who have received one prior line of therapy.

The study focuses on patients with PDAC harboring specific RAS mutations. Primary endpoints are progression-free survival (PFS) and overall survival (OS) in the core patient population. This milestone marks a significant step in Revolution Medicines' mission to revolutionize treatment for RAS-addicted cancers, particularly PDAC, which has a five-year survival rate of only 3% in metastatic cases.

Revolution Medicines (Nasdaq: RVMD) announced seven presentations at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. Two late-breaking presentations will feature new clinical data on pancreatic ductal adenocarcinoma (PDAC) patients treated with RMC-6236 and RMC-9805. The presentations include:

1. Updated safety and efficacy data from the RMC-6236 monotherapy study
2. Initial safety and antitumor activity data from the RMC-9805 first-in-human monotherapy study
3. Five additional presentations on various RAS inhibitors and their effects

Revolution Medicines will host an investor webcast on October 25, 2024, focusing on PDAC data from the RMC-6236 and RMC-9805 monotherapy studies. Further updates on the company's RAS(ON) inhibitor clinical development programs will be provided later in the quarter.

Revolution Medicines (Nasdaq: RVMD) reported its Q2 2024 financial results and corporate progress. Key highlights include:

1. Advancing RMC-6236 into pivotal trials for pancreatic and lung cancer

2. Expanding RMC-6236 into earlier treatment lines

3. Progressing RMC-6291 and RMC-9805 for late-stage development

4. Appointment of Frank Clyburn to the board of directors

5. Q2 financial results: $1.59 billion cash position, $134.9 million R&D expenses, $21.7 million G&A expenses, and $133.2 million net loss

6. Reiterated 2024 GAAP net loss guidance of $560-600 million

7. Current cash can fund operations into 2027

Revolution Medicines (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies for RAS-addicted cancers, has announced its plan to release second quarter 2024 financial results on August 7, 2024, after market close. The company's senior management will host a webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and provide a corporate progress update. Interested parties can access the live webcast or replay through the company's investor relations website. The replay will be available for at least 14 days following the live event.

Revolution Medicines (Nasdaq: RVMD) announced the publication of a study in Cancer Discovery demonstrating the efficacy of their RAS(ON) multi-selective inhibitor, RMC-7977, in preclinical models of KRAS-mutated non-small cell lung cancer (NSCLC). The inhibitor showed strong anti-tumor activity alone and in combination with the RAS(ON) G12C-selective inhibitor, RMC-4998. This combination resulted in significant tumor regression and prolonged time to tumor doubling, particularly in models resistant to current therapies. The study also identified long-term tumor cell persistence mechanisms, providing insights for future treatments. Revolution Medicines plans to conduct further trials with their investigational drug RMC-6236, aimed at treating various RAS-driven cancers.

Revolution Medicines (Nasdaq: RVMD) will host an investor webcast to update on its RMC-6236 pancreatic ductal adenocarcinoma (PDAC) clinical development program. The webcast is scheduled for July 15, 2024, at 8:00 a.m. Eastern Time. Speakers include the company's management and Dr. Brian M. Wolpin from Harvard Medical School and Dana-Farber Cancer Institute. The event can be accessed via the company's 'Events & Presentations' page. A replay will be available for 14 days post-event.

Revolution Medicines (Nasdaq: RVMD), a clinical-stage oncology company focusing on targeted therapies for RAS-addicted cancers, announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference. CEO Mark A. Goldsmith will present at a fireside chat on June 12, 2024, at 2:40 p.m. ET. The event will be held at the Loews Miami Beach Hotel in Miami, FL, with a live webcast accessible via the company's website. A replay will be available for 14 days post-conference.